PMC7098338_01
Clinical courses of ADPKD patients who received tolvaptan therapy. A Case 1. B Case 2. Solid line: estimated glomerular filtration rate (eGFR); gray bar: total kidney volume.
cnd-0010-0009-g01.jpg
PMC7098338_02_cnd-0010-0009-g01.jpg
F1
TKV determined with an ellipsoid equation increased from 1,290 mL before starting tolvaptan treatment to 2,570 mL at the most recent examination, for an annual rate of increase of 11.0% (Fig. 1B). TKV in case 2 showed a gradual increase, from 4.7% per year in the initial 3-year period to 12.5 % per year in the most recent 6-year period.
PMC7098338_02
Clinical courses of ADPKD patients who received tolvaptan therapy. A Case 1. B Case 2. Solid line: estimated glomerular filtration rate (eGFR); gray bar: total kidney volume.
cnd-0010-0009-g01.jpg
PMC7098338_02_cnd-0010-0009-g01.jpg
F1
TKV determined with an ellipsoid equation increased from 1,290 mL before starting tolvaptan treatment to 2,570 mL at the most recent examination, for an annual rate of increase of 11.0% (Fig. 1B). TKV in case 2 showed a gradual increase, from 4.7% per year in the initial 3-year period to 12.5 % per year in the most recent 6-year period.